ImmunityBio, a company focused on immunotherapy for cancer and infectious diseases, saw its stock surge by nearly 40%, closing at $5.52 on Friday, January 16, 2026, following a series of promising announcements. The impressive 39.75% increase reflects robust growth in revenue for its leading drug, Anktiva, along with positive trial data and recent regulatory approvals.
Trading activity was notably high, with nearly 178 million shares changing hands—over 1,200% more than the average trading volume of 13 million shares in recent months. Such a dramatic spike in volume indicates significant investor interest, likely influenced by the preliminary revenue figures released earlier that day. According to the update, Anktiva is projected to generate approximately $113 million in net product revenue for 2025, marking a staggering year-over-year growth of 700% and an increase of 431% for the quarter alone.
Analysis of the recent announcements highlights substantial advancements in ImmunityBio’s oncology pipeline, particularly regarding its bladder cancer treatments. The favorable clinical trial outcomes have boosted expectations for an upcoming application for regulatory approval, further encouraging investor confidence.
The stock movement may also be attributed to known short interest levels, suggesting that some of the price increase could stem from short sellers covering their positions. This combination of positive news and market dynamics has created an optimistic atmosphere for current shareholders and potential investors.
In the broader market context, major indices displayed minimal changes; the S&P 500 and the Nasdaq Composite each fell by 0.06%. However, other companies in the oncology sector, such as Iovance Biotherapeutics and Krystal Biotech, noted minor gains, indicating a broader reassessment among investors of oncology-focused firms.
ImmunityBio’s recent performance stands in stark contrast to its IPO debut in 2015, during which the company has experienced an overall decline of 85%. The rapid uptick in stock price and trading volume, fueled by a promising outlook for Anktiva, suggests a potential turnaround for the firm as it navigates the complex landscape of immunotherapy development.
Overall, the developments surrounding ImmunityBio not only redefine its prospects within the biopharmaceutical industry but also potentially signal a resurgence for the company, as attention turns to forthcoming plans for Biologics License Applications (BLA) and further commercialization of Anktiva.
